Navigation Links
IMPAKT -- Breast cancer conference highlights
Date:5/7/2009

If you are interested in receiving the full text of the press releases and the related abstracts, please contact media@esmo.org

Please note that all news releases are embargoed until Thursday, 7 May 2009, 14:00 (CEST)

GENE SIGNATURE IDENTIFIES BREAST CANCER PATIENTS WHO WILL RESPOND TO CHEMOTHERAPY
Thursday, 7 May 2009 (17:00)

Researchers have identified a genetic signature that can predict which breast cancer patients will respond well to treatment with epirubicin, a widely used form of chemotherapy. Although among the most effective chemotherapies in breast cancer, a small proportion of women suffer severe side-effects. By identifying those women who are most likely to benefit from treatment, doctors may be able to ensure fewer women are unnecessarily exposed to that risk. The new study shows that this goal can be achieved by developing more sophisticated ways to use older drugs.

GENE SIGNATURE PREDICTS GOOD OUTCOME IN BREAST CANCER
Friday 8 May 2009 (08:30)

Researchers have identified a genetic signature that can predict an improved clinical outcome in patients with breast cancer, and which could help in the development of new targeted therapies. By analysing the expression of different genes induced by a specific mutation in a molecule called PIK3CA, a critical part of the pathway commonly deregulated in breast cancer, they found that these genes were correlated with an improved clinical outcome in over 1500 women with the disease.

GENETIC TEST REDUCES NEED FOR SECOND SURGERY IN BREAST CANCER TREATMENT
Friday, 8 May 2009 (15:15)

A new rapid test can confirm quickly and accurately that breast cancer has most likely not spread into adjacent lymph nodes, offering reassurance to patients and reducing the need for a second operation. The new technique allows you to make the diagnosis of micro metastases while the surgery is underway, meaning the patient does not have to suffer the disruption of undergoing another operation.

ANDROGEN-RECEPTOR: A NEW DRUG TARGET IN BREAST CANCER
Friday, 8 May 2009 (16:30)

New results may help scientists develop treatments for women with a type of breast cancer that currently does not respond to targeted therapies. Some cancers (triple-negative tumors) generally do not respond to receptor-targeted treatments. In recent years, scientists have begun looking for new targets in these "triple-negative" cancers. One that has been identified is the androgen-receptor.


'/>"/>

Contact: ESMO Press Office
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Newly created cancer stem cells could aid breast cancer research
2. Linchpin gene may be useful target for new breast cancer therapies
3. Dietary calcium could possibly prevent the spread of breast cancer to bone
4. Researchers find new gene linked to breast cancer
5. Analysis of breast and colon cancer genes finds many areas of differences between tumors
6. Genome update defines landscape of breast and colon cancers
7. AACR, BCRF award inaugural grants in translational breast cancer research
8. Enhanced DNA-repair mechanism can cause breast cancer
9. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
10. Breast cancer research and inkjet tissue printing get NSF boost
11. Breastfeeding boost IQ in infants with helpful genetic variant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
Breaking Biology Technology: